Hi-Tech Pharmacal's ECR Pharmaceuticals Subsidiary to Co-Promote Unique Kidney Stone Treatment

Published: Feb 16, 2010

AMITYVILLE, N.Y.--(BUSINESS WIRE)--Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced today that its branded marketing subsidiary, ECR Pharmaceuticals will promote UrocitĀ®-K 15mEq, potassium citrate extended release tablets to primary care physicians beginning in April, 2010. Hi-Tech has a license agreement with Mission Pharmacal Company, which will promote the product to Urologists. Indicated for the treatment of kidney stones, UroCitĀ®-K 15mEq is the maximum strength potassium citrate product available, and provides convenient twice-a-day dosing Urocit-K 15 mEq offers kidney stone sufferers the only twice-daily treatment at this dosage strength. The new formulation provides patients with 50 percent more of the active ingredient, potassium citrate, than Urocit-K 10 mEq. ECR Pharmaceuticals will receive a percentage of gross profit based on prescriptions generated by primary care physicians.

Back to news